Novavax Announces Leadership Promotions
December 04 2018 - 4:05PM
Novavax Announces Leadership Promotions
Novavax, Inc. (Nasdaq: NVAX) today announced the promotion of Jill
Hoyt to Senior Vice President of Human Resources and Biegie Lee to
Vice President of Information Technology.
“I am thrilled to announce these two important
management promotions; Jill and Biegie are vital parts of a
seasoned executive team striving to accomplish our near and
long-term corporate objectives," said Stanley Erck, President and
Chief Executive Officer of Novavax, Inc. “Jill has been working
with me and the senior leadership team to hire, develop and support
employees of this company, which is consistently being recognized
as one of the best in the biopharmaceutical industry. Biegie has
been leading Novavax’ efforts to preserve, protect and support our
robust IT infrastructure, an important function given our needs
around the ongoing management of enourmous amounts of data with
complex information system tools.”
Ms. Hoyt joined Novavax in 2008 with full
responsibility for its human resources duties and activities. Her
significant expertise and experiences were pivotal in the
development and expansion of the company’s employee base in both
the U.S. and Sweden. Ms. Hoyt has implemented leadership strategies
for the development of comprehensive human resources programs in
support of the company’s strategic plans, while also driving
cultural development, for which Novavax has been recognized several
times, including placement on Washington Post’s Top Workplaces. Ms.
Hoyt earned her Master’s degree in Human Resource Management from
Marymount University and her Bachelor’s degree in Business
Administration from Shepherd University.
In his role as Vice President, Information
Technology (IT), Mr. Lee is responsible for leading Novavax’
information technology operations, network infrastructure,
enterprise applications, project management and cybersecurity
programs. He works closely with senior management to align IT
investments with corporate strategy and business objectives. He
joined Novavax in 2017 with more than 20 years of IT experience,
the vast majority of which has been in the life sciences industry.
Mr. Lee previously held positions of increasing responsibility at
Human Genome Sciences (HGS) leading up to its acquisition by
GlaxoSmithKline (GSK). He also led the global IT integration and
successfully completed the disposition of all IT assets during the
transition of HGS into GSK.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a late-stage
biotechnology company that drives improved health globally through
the discovery, development, and commercialization of innovative
vaccines to prevent serious infectious diseases. ResVax™, its RSV
vaccine for infants via maternal immunization, is the only vaccine
in a Phase 3 clinical program and is designed to prevent the second
leading cause of death in children under one year of age worldwide.
Novavax is also advancing NanoFlu™, its quadrivalent influenza
nanoparticle vaccine, to address key factors that can lead to the
poor effectiveness of currently approved flu vaccines. Novavax is a
leading innovator of recombinant vaccines; its proprietary
recombinant technology platform combines the power and speed of
genetic engineering to efficiently produce a new class of highly
immunogenic nanoparticles addressing urgent global health
needs.
For more information, visit www.novavax.com and
connect with us on Twitter and LinkedIn.
Contacts:
InvestorsNovavax, Inc.Erika Trahanir@novavax.com240-268-2000
Westwicke PartnersJohn
Woolfordjohn.woolford@westwicke.com443-213-0506
MediaSam BrownMike Beyermikebeyer@sambrown.com312-961-2502
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Sep 2023 to Sep 2024